COMMUNIQUÉS West-GlobeNewswire
-
Tris Pharma Announces FDA Grant of Orphan Drug Designation for TRN-257 (Oxybate for Extended-Release Oral Suspension) a Once-Nightly, Low-Sodium Oxybate Product for Idiopathic Hypersomnia
10/06/2026 -
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
10/06/2026 -
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
10/06/2026 -
BMGL to Effect Reverse Share Split on June 22, 2026
10/06/2026 -
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
10/06/2026 -
Ligand Announces 2026 Investor Day in New York City
10/06/2026 -
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
10/06/2026 -
Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
10/06/2026 -
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
10/06/2026 -
Tilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in Germany
10/06/2026 -
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
10/06/2026 -
Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment
10/06/2026 -
Italfarmaco annonce l’acceptation du dépôt et l’examen prioritaire par Santé Canada pour la présentation de drogue nouvelle du givinostat dans le traitement de la dystrophie musculaire de Duchenne
10/06/2026 -
Reacta Healthcare Receives Extended MHRA Pharmaceutical Manufacturer’s Licence and GMP Certificate
10/06/2026 -
IBA annonce une collaboration de recherche visant à renforcer les preuves sur la valeur de la protonthérapie
10/06/2026 -
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
10/06/2026 -
Communiqué de presse : Sanofi fait le point sur l’étude de phase 3 MOBILIZE, qui évalue le riliprubart dans la polyneuropathie inflammatoire démyélinisante chronique
10/06/2026 -
China's Leading Brand CUKTECH has Cumulatively Sold Over 150 Million Power Banks Globally, Taking a Further Step Towards Globalization
10/06/2026 -
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
10/06/2026
Pages